On March 15th, the RNA Research Center of IBS (Institute of Basic Science) of the Seoul National University and Korea Centers for Disease Control & Prevention used MGI’s DNBSEQ™ technology with Nanopore single-molecule sequencing technology to analyze the total RNA of Vero cells infected by the novel coronavirus. The analysis, combined with previous research, provided high-definition maps of the novel coronavirus transcriptome and epitranscriptome. Sequencing data shows that the sequenc...

With the in-depth development of "precision medicine", high-throughput sequencing technology has ushered in greater development space, and the industry has also put forward higher requirements for its accuracy, comprehensiveness, and sensitivity. In the face of such requirements, at the 2019 International Genomics Conference (ICG-14), MGI made a series of antibody-based sequencing reagents; the CoolMPS high-throughput sequencing reagent kit was released. According to public information, C...

Recently, the National Health and Medical Commission issued the "Novel Coronavirus Virus Pneumonia Diagnosis and Treatment Plan (Seventh Edition)". The new version of the diagnosis and treatment plan mainly adjusted the following: the epidemic prevention situation prompts vigilance against imported cases abroad; the increase in the transmission route "should pay attention to feces and urine to the environmental contamination caused by aerosol or exposure "; increased description of clinica...

The brain is the most complex organ in mammals, with a variety of physiological functions, intricate cellular structures, and extremely rich gene expression. Identifying the molecular composition of the brain at different brain regions, cells and subcellular levels will definitely advance our understanding of Understanding and understanding of brain function in normal and diseased states. On March 5, U.S time, a study titled "Maps of protein-coding genes in the brains of humans, pigs, and...

MGI responded to a complaint filed by Illumina on February 27 in the US District Court for the Northern District of California against MGI’s DNBSEQ™ sequencing instruments and MPS reagents. MGI believes that this complaint is completely without merit and an obvious attempt by Illumina to maintain a monopolistic market position and prevent choice from being offered to customers. We intend to vigorously defend our intellectual property, as we have in other jurisdictions, and strive for c...

SAN JOSE, CA, Feb. 27, 2020– MGI, part of the global genomics leader BGI Group, announced an agreement with SOPHiA GENETICS to provide MGI’s customers access to the SOPHiA Platform for data analysis and interpretation. By combining MGI’s DNBSEQ™ sequencing technology with SOPHiA’s Platform, MGI provides an effective solution for clinical researchers and further drives adoption of MGI’s genetic sequencers. Under the terms of the non-exclusive agreement, MGI’s customers will have the ...